Accessible mutational trajectories for the evolution of pyrimethamine resistance in the malaria parasite plasmodium vivax

Journal of Molecular Evolution

Volumn 77, Issue 3, 2013, Pages 81-91

  Jiang, Pan Pan ^a   Corbett Detig, Russell B ^a   Hartl, Daniel L ^a   Lozovsky, Elena R ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Dihydrofolate reductase; Drug resistance; Fitness landscape; Malaria; Plasmodium vivax; Pyrimethamine

Indexed keywords

ANTIMALARIAL AGENT; DIHYDROFOLATE REDUCTASE; PYRIMETHAMINE;

ALLELE; ARTICLE; DRUG EFFECT; DRUG RESISTANCE; GENE LOCUS; GENETICS; IC 50; METABOLISM; MOLECULAR EVOLUTION; MUTATION; PLASMODIUM VIVAX; SACCHAROMYCES CEREVISIAE;

ALLELES; ANTIMALARIALS; DRUG RESISTANCE; EVOLUTION, MOLECULAR; GENETIC LOCI; INHIBITORY CONCENTRATION 50; MUTATION; PLASMODIUM VIVAX; PYRIMETHAMINE; SACCHAROMYCES CEREVISIAE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84885671999     PISSN: 00222844     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00239-013-9582-z     Document Type: Article

References (53)

1. Aharoni A, Gaidukov L, Khersonsky O et al (2005) The 'evolvability' of promiscuous protein functions. Nat Genet 37:73-76
2. Ahmed A, Das MK, Dev V et al (2006) Quadruple mutations in dihydrofolate reductase of Plasmodium falciparum isolates from Car Nicobar Island, India. Antimicrob Agents Chemother 50:1546-1549
3. Anderson TJC, Nair S, Sudimack D et al (2005) Geographical distribution of selected and putatively neutral SNPs in Southeast Asian malaria parasites. Mol Biol Evol 22:2362-2374
4. Ayala FJ, Escalante AA, Rich SM (1999) Evolution of Plasmodium and the recent origin of the world populations of Plasmodium falciparum. Parasitologia 41:55-68
5. Berkhout B (1999) HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci 6:298-305
6. Breman JG (2012) Resistance to artemisinin-based combination therapy. Lancet Infect Dis 12:820-822
7. Brown KM, Costanzo MS, Xu W et al (2010) Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol Biol Evol 27:2682-2690
8. Carter R (2003) Speculations on the origins of Plasmodium vivax malaria. Trends Parasitol 19:214-219
9. Chang H-H, Park DJ, Galinsky KJ et al (2012) Genomic sequencing of Plasmodium falciparum malaria parasites from senegal reveals the demographic history of the population. Mol Biol Evol 29:3427-3439
10. Choowongkomon K, Theppabutr S, Songtawee N et al (2010) Computational analysis of binding between malarial dihydrofolate reductases and anti-folates. Malar J 9:65
11. Chou H-H, Chiu H-C, Delaney NF et al (2011) Diminishing returns epistasis among beneficial mutations decelerates adaptation. Science 332:1190-1192
12. Cortese JF, Plowe CV (1998) Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol Biochem Parasitol 94:205-214
13. Cowman AF, Morry MJ, Biggs BA et al (1988) Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 85:9109-9113
14. de Pécoulas PE, Tahar R, Ouatas T et al (1998) Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol 92:265-273
15. Depristo MA, Zilversmit MM, Hartl DL (2006) On the abundance, amino acid composition, and evolutionary dynamics of low-complexity regions in proteins. Gene 378:19-30
16. Gregson A, Plowe CV (2005) Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 57:117-145
17. Hastings MD, Porter KM, Maguire JD et al (2004) Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis 189:744-750
18. Hawkins VN, Joshi H, Rungsihirunrat K et al (2007) Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol 23:213-222
19. Hawkins VN, Auliff A, Prajapati SK et al (2008) Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase. Malar J 7:72
20. Howell EE, Foster PG, Foster LM (1988) Construction of a dihydrofolate reductase-deficient mutant of Escherichia coli by gene replacement. J Bacteriol 170:3040-3045
21. Hyde JE (2005) Drug-resistant malaria. Trends Parasitol 21:494-498
22. Joseph SB, Hall DW (2004) Spontaneous mutations in diploid Saccharomyces cerevisiae: more beneficial than expected. Genetics 168:1817-1825
23. Kepler TB, Perelson AS (1998) Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci USA 95:11514-11519
24. Khim N, Kim S, Bouchier C et al (2012) Reduced impact of pyrimethamine drug pressure on Plasmodium malariae dihydrofolate reductase gene. Antimicrob Agents Chemother 56:863-868
25. Kompis IM, Islam K, Then RL (2005) DNA and RNA synthesis: antifolates. Chem Rev 105:593-620
26. Kondrashov FA (2005) In search of the limits of evolution. Nat Genet 37:9-10
27. Kongsaeree P, Khongsuk P, Leartsakulpanich U et al (2005) Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA 102:13046-13051
28. Leartsakulpanich U, Imwong M, Pukrittayakamee S et al (2002) Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol Biochem Parasitol 119:63-73
29. Looareesuwan S, Viravan C, Webster HK et al (1996) Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54:62-66
30. Lozovsky ER, Chookajorn T, Brown KM et al (2009) Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA 106:12025-12030
31. Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64:97-106
32. Nair S, Miller B, Barends M et al (2008) Adaptive copy number evolution in malaria parasites. PLoS Genet 4:e1000243
33. Neafsey DE, Galinsky K, Jiang RHY et al (2012) The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nat Genet 44:1046-1050
34. Parekh F, Moorthy V (2011) Plasmodium vivax vaccine research: insights from Colombian studies. Am J Trop Med Hyg 84:1
35. Peng B, Kimmel M (2005) simuPOP: a forward-time population genetics simulation environment. Bioinformatics 21:3686-3687
36. Peterson DS, Walliker D, Wellems TE (1988) Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85:9114-9118
37. Randrianasolo L, Randriamanantena A, Ranarivelo L et al (2004) Monitoring susceptibility to sulfadoxine-pyrimethamine among cases of uncomplicated, Plasmodium falciparum malaria in Saharevo, Madagascar. Ann Trop Med Parasitol 98:551-554
38. Rastelli G, Sirawaraporn W, Sompornpisut P et al (2000) Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance. Bioorg Med Chem 8:1117-1128
39. Sibley CH, Hyde JE, Sims PF et al (2001) Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 17:582-588
40. Sikorski RS, Hieter P (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27
41. Simpson JA, Watkins E, Price RN et al (2000) Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 44:3414-3424
42. Sina B (2002) Focus on Plasmodium vivax. Trends Parasitol 18:287-289
43. Sirawaraporn W, Sathitkul T, Sirawaraporn R et al (1997) Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 94:1124-1129
44. Snewin VA, England SM, Sims PF, Hyde JE (1989) Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene 76:41-52
45. Tjitra E, Baker J, Suprianto S et al (2002) Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 46:3947-3953
46. Tokuriki N, Jackson CJ, Afriat-Jurnou L, Wyganowski KT, Tang R, Tawfik DS (2012) Diminishing returns and tradeoffs constrain the laboratory optimization of an enzyme. Nat Commun 3:1257
47. van den Broek IVF, van der Wardt S, Talukder L et al (2004) Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh. Trop Med Int Health 9:680-687
48. Wang X, Minasov G, Shoichet BK (2002) Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 320:85-95
49. Weinreich DM, Delaney NF, Depristo MA, Hartl DL (2006) Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111-114
50. Wellems TE (2002) Plasmodium chloroquine resistance and the search for a replacement antimalarial drug. Science 298:124-126
51. White NJ, Pongtavornpinyo W, Maude RJ et al (2009) Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8:253-271
52. Wooden JM, Hartwell LH, Vasquez B, Sibley CH (1997) Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol Biochem Parasitol 85:25-40
53. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S et al (2003) Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 10:357-365